Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
 Bcr-Abl and Lyn protein kinase inhibitor INNO 406, 2 mg  

Bcr-Abl and Lyn protein kinase inhibitor INNO 406, 2 mg

(S)-N-(3-(4,5'-bipyrimidin-2-ylamino)-4-methylphenyl)-4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzamide

INNO 406 is an orally bioavailable dual Bcr-Abl and Lyn kinase inhibitor with anti-CML efficacy

More details

PKI-INNO406-002

Availability: within 3 days

144,50 €

Background: INNO 406 is an orally bioavailable dual Bcr-Abl and Lyn kinase inhibitor with anti-CML efficacy; orally bioavailable; more potent (>10 times) than Imatinib; highly recommended Abl inhibitor in treating chronic myeloid leukaemia (CML).

Chemical formula: C30H31F3N8O
Molecular weight: 576.62 g/mol
Purity: 99%
Optical purity: Optically pure
Appearance: Off-white solid
Solubility: Soluble in 0.1N HCl(aq) and DMSO
CAS Number: 859212-16-1

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers.  

References

A Yokota et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood, 2007, 109(1), 306-314.
 
H Kantarjian et al. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer, 2010, 116(11), 2665-72.
 
JC Uitdehaag et al. A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. Br. J. Pharmacol. 2012, 166, 858–876.

The following products could also be interesting for you: